Navigation Links
Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
Date:10/16/2007

- Isis will own 18 percent of Altair and will receive milestones and

royalties on antisense drugs developed by Altair

- Altair to conduct clinical development of ISIS 369645 for asthma

CARLSBAD, Calif. and SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Thomas, McNerney & Partners, LLC, announced today that Altair Therapeutics Inc., a new venture capital-funded biotechnology company, has been created to focus on the discovery, development and commercialization of Isis' antisense drugs to treat asthma and other respiratory conditions. Isis has granted an exclusive worldwide license to Altair for the development and commercialization of ISIS 369645, an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment of asthma. Isis and Altair will also be collaborating to discover drugs directed to other promising targets for the treatment of respiratory conditions. Isis will own 18 percent of Altair in the form of preferred stock. Furthermore, as ISIS 369645 and other drugs arising out of the research collaboration progress, Altair will pay Isis development milestones and royalties.

"Altair is assembling a focused team of experts in both antisense drug discovery and development and respiratory conditions to advance antisense drugs, including ISIS 369645," said Jeff Jonas, M.D., Executive Vice President of Isis. "Our robust antisense technology allows us to continue to discover and validate many more drug candidates than we can advance ourselves. Altair is the most recent example of our satellite company strategy; through this strategy we expand therapeutic applications for antisense drugs while focusing our internal resources in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Jellyfish partners for sales tracking technology
4. GE Healthcare partners with UNC on breast cancer imaging research
5. Manufacturing partnership will move into biotech and biomedical spaces
6. Fergus joins Baird Venture Partners, Caden Bio
7. Avolte Venture Partners reaches capital goal
8. NimbleGen partners with UK biotech firm
9. Big pharma seeks Wisconsin biotech partnerships
10. Thompson in partnership to build ethanol plant
11. Johnson Controls partners on car satellite linkup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is ... as Head of Clinical and Regulatory Services. Shalabh is a ... a co-founder and CEO of Kinapse, as well as a ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Tizzard commented "I am delighted to welcome Shalabh into ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... , April 23, 2015 WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology ... China and the United States ... results for the first quarter of 2015 after the ... 2015 (which will be Thursday morning, May 14, 2015 ...
(Date:4/23/2015)... Glemser Technologies is ... Enterprise Content Division (ECD) Certified Solution Partner to ... for Life Sciences Solution Suite . The accreditation ... to provide life sciences companies of all sizes ... EMC Documentum Solution Suite offers four modules: Quality ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Genomas(R), a,biomedical company advancing DNA-guided medicine and ... Phase I-II Small,Business Innovation Research (SBIR) Grant totaling ... Statin Safety and Efficacy," was,awarded by the National ... are the most prescribed drugs in the world. ...
... to Attend April Meeting,in St. Louis, DANBURY, ... (SBS) today announced its outstanding roster of,keynote speakers ... be held,April 6-10 at America,s Center in St. ... and biotech industries from around the world are,expected ...
Cached Biology Technology:3SBio Inc. Approves Share Repurchase Program 2Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy 2Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... PITTSBURGHCarnegie Mellon University,s John Kitchin was awarded $750,000 ... of Energy for developing new materials for producing ... was elated to hear that my research had been ... professor in Chemical Engineering at Carnegie Mellon. "This ...
... distinctive red soils could play a part in the formation ... off east coast beaches in summer., A QUT team of ... gives our iron-rich soil its red colour, reaches water to ... a foul smell, but also make our eyes sting, cause ...
... This release is available in German . ... decreased over recent decades. In fact, the number of beekeepers has ... the result of a study that has now been published by ... provided an overview of the problem of bee colony decline at ...
Cached Biology News:Carnegie Mellon's John Kitchin receives early career award 2Is iron from soil a factor in algal blooms? 2Fewer honey bee colonies and beekeepers throughout Europe 2Fewer honey bee colonies and beekeepers throughout Europe 3
Request Info...
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
... 75 x 25 mm; ... recommended for immunohistochemistry of paraffin-embedded sections, ... end, markings will not ... precleaned, ...
Complete cell culture media with cytokines...
Biology Products: